Literature DB >> 20179193

The dicey role of Dicer: implications for RNAi therapy.

William M Merritt1, Menashe Bar-Eli, Anil K Sood.   

Abstract

The dynamic properties of RNA interference (RNAi) in cancer biology have led investigators to pursue with significant interest its role in tumorigenesis and cancer therapy. We recently reported that decreased expression of key RNAi enzymes, Dicer and Drosha, in epithelial ovarian cancers was associated with poor clinical outcome in patients. Dicer expression was also functionally relevant in that targeted silencing was limited with RNAi fragments that require Dicer function compared with those that do not. Together, this and other studies suggest that RNAi machinery expression may affect key pathways in tumorigenesis and cancer biology. Understanding alterations in the functional RNAi machinery is of fundamental importance as we strive to develop novel therapies using RNAi strategies.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20179193      PMCID: PMC3170915          DOI: 10.1158/0008-5472.CAN-09-2536

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  32 in total

Review 1.  RNA interference.

Authors:  Gregory J Hannon
Journal:  Nature       Date:  2002-07-11       Impact factor: 49.962

Review 2.  Strategies for silencing human disease using RNA interference.

Authors:  Daniel H Kim; John J Rossi
Journal:  Nat Rev Genet       Date:  2007-03       Impact factor: 53.242

3.  Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans.

Authors:  A Fire; S Xu; M K Montgomery; S A Kostas; S E Driver; C C Mello
Journal:  Nature       Date:  1998-02-19       Impact factor: 49.962

4.  Reduced expression of Dicer associated with poor prognosis in lung cancer patients.

Authors:  Yoko Karube; Hisaaki Tanaka; Hirotaka Osada; Shuta Tomida; Yoshio Tatematsu; Kiyoshi Yanagisawa; Yasushi Yatabe; Junichi Takamizawa; Shinichiro Miyoshi; Tetsuya Mitsudomi; Takashi Takahashi
Journal:  Cancer Sci       Date:  2005-02       Impact factor: 6.716

5.  Focal adhesion kinase targeting using in vivo short interfering RNA delivery in neutral liposomes for ovarian carcinoma therapy.

Authors:  Jyotsnabaran Halder; Aparna A Kamat; Charles N Landen; Liz Y Han; Susan K Lutgendorf; Yvonne G Lin; William M Merritt; Nicholas B Jennings; Arturo Chavez-Reyes; Robert L Coleman; David M Gershenson; Rosemarie Schmandt; Steven W Cole; Gabriel Lopez-Berestein; Anil K Sood
Journal:  Clin Cancer Res       Date:  2006-08-15       Impact factor: 12.531

Review 6.  A small piece in the cancer puzzle: microRNAs as tumor suppressors and oncogenes.

Authors:  O A Kent; J T Mendell
Journal:  Oncogene       Date:  2006-10-09       Impact factor: 9.867

7.  RAS is regulated by the let-7 microRNA family.

Authors:  Steven M Johnson; Helge Grosshans; Jaclyn Shingara; Mike Byrom; Rich Jarvis; Angie Cheng; Emmanuel Labourier; Kristy L Reinert; David Brown; Frank J Slack
Journal:  Cell       Date:  2005-03-11       Impact factor: 41.582

8.  Adeno-associated virus vectors for short hairpin RNA expression.

Authors:  Dirk Grimm; Kusum Pandey; Mark A Kay
Journal:  Methods Enzymol       Date:  2005       Impact factor: 1.600

9.  Dicer, Drosha, and outcomes in patients with ovarian cancer.

Authors:  William M Merritt; Yvonne G Lin; Liz Y Han; Aparna A Kamat; Whitney A Spannuth; Rosemarie Schmandt; Diana Urbauer; Len A Pennacchio; Jan-Fang Cheng; Alpa M Nick; Michael T Deavers; Alexandra Mourad-Zeidan; Hua Wang; Peter Mueller; Marc E Lenburg; Joe W Gray; Samuel Mok; Michael J Birrer; Gabriel Lopez-Berestein; Robert L Coleman; Menashe Bar-Eli; Anil K Sood
Journal:  N Engl J Med       Date:  2008-12-18       Impact factor: 91.245

Review 10.  microRNAs and cancer: an overview.

Authors:  Pedro P Medina; Frank J Slack
Journal:  Cell Cycle       Date:  2008-08-17       Impact factor: 4.534

View more
  31 in total

1.  Comprehensive evaluation of canonical versus Dicer-substrate siRNA in vitro and in vivo.

Authors:  Donald J Foster; Scott Barros; Rick Duncan; Sarfraz Shaikh; William Cantley; Amy Dell; Elena Bulgakova; Jonathan O'Shea; Nate Taneja; Satya Kuchimanchi; Christopher B Sherrill; Akin Akinc; Gregory Hinkle; Amy C Seila White; Bo Pang; Klaus Charisse; Rachel Meyers; Muthiah Manoharan; Sayda M Elbashir
Journal:  RNA       Date:  2012-01-31       Impact factor: 4.942

2.  DICER1 expression and outcomes in endometrioid endometrial adenocarcinoma.

Authors:  Israel Zighelboim; Andrew J Reinhart; Feng Gao; Amy P Schmidt; David G Mutch; Premal H Thaker; Paul J Goodfellow
Journal:  Cancer       Date:  2010-11-08       Impact factor: 6.860

Review 3.  Translational application of epigenetic alterations: ovarian cancer as a model.

Authors:  Marie E Maradeo; Paul Cairns
Journal:  FEBS Lett       Date:  2011-03-12       Impact factor: 4.124

4.  AKI Recovery Induced by Mesenchymal Stromal Cell-Derived Extracellular Vesicles Carrying MicroRNAs.

Authors:  Federica Collino; Stefania Bruno; Danny Incarnato; Daniela Dettori; Francesco Neri; Paolo Provero; Margherita Pomatto; Salvatore Oliviero; Ciro Tetta; Peter J Quesenberry; Giovanni Camussi
Journal:  J Am Soc Nephrol       Date:  2015-04-21       Impact factor: 10.121

5.  Depletion of Dicer promotes epithelial ovarian cancer progression by elevating PDIA3 expression.

Authors:  Ying Zhu; Liqiong Cai; Jing Guo; Na Chen; Xiaoqing Yi; Yong Zhao; Jing Cai; Zehua Wang
Journal:  Tumour Biol       Date:  2016-08-05

6.  Functional importance of Dicer protein in the adaptive cellular response to hypoxia.

Authors:  J J David Ho; Julie L Metcalf; Matthew S Yan; Paul J Turgeon; Jenny Jing Wang; Maria Chalsev; Tania N Petruzziello-Pellegrini; Albert K Y Tsui; Jeff Z He; Helena Dhamko; H S Jeffrey Man; G Brett Robb; Bin T Teh; Michael Ohh; Philip A Marsden
Journal:  J Biol Chem       Date:  2012-06-28       Impact factor: 5.157

7.  Expression of the ribonucleases Drosha, Dicer, and Ago2 in colorectal carcinomas.

Authors:  Dionysios J Papachristou; Angeliki Korpetinou; Efstathia Giannopoulou; Anna G Antonacopoulou; Helen Papadaki; Petros Grivas; Chrisoula D Scopa; Haralabos P Kalofonos
Journal:  Virchows Arch       Date:  2011-07-18       Impact factor: 4.064

Review 8.  RNA interference in the clinic: challenges and future directions.

Authors:  Chad V Pecot; George A Calin; Robert L Coleman; Gabriel Lopez-Berestein; Anil K Sood
Journal:  Nat Rev Cancer       Date:  2010-12-16       Impact factor: 60.716

9.  Drosha regulates hMSCs cell cycle progression through a miRNA independent mechanism.

Authors:  Adam Z Oskowitz; Patrice Penfornis; Alan Tucker; Darwin J Prockop; Radhika Pochampally
Journal:  Int J Biochem Cell Biol       Date:  2011-07-20       Impact factor: 5.085

10.  Arlm1 is a male-specific modifier of astrocytoma resistance on mouse Chr 12.

Authors:  Jessica C Amlin-Van Schaick; Sungjin Kim; Christina DiFabio; Min-Hyung Lee; Karl W Broman; Karlyne M Reilly
Journal:  Neuro Oncol       Date:  2012-01-10       Impact factor: 12.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.